Regression of vasomotor disorders under intrathecal baclofen in a case of spastic paraplegia.
Continuous intrathecal baclofen infusion via a subcutaneously implanted programmable pump has been used in the treatment of severe spasticity. Improvement classically concerns the neurological (hypertonia, spasms, hyperreflexia), urological (bladder function) and other clinically relevant outcomes, such as functional status of daily living. This short note reports on another effect of intrathecal baclofen on vasomotor disorders and cyanosis in the lower limbs, described in a patient with spastic paraplegia.
Rode
G
G
Service de Rééducation Neurologique Hospices Civil de Lyon, France.
Mertens
P
P
Beneton
C
C
Schmitt
M
M
Boisson
D
D
D000328:Adult; D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use*; D004185:Disability Evaluation; D006801:Humans; D015918:Infusion Pumps, Implantable; D008297:Male; D009048:Motor Skills / Q000187:drug effects*; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D010264:Paraplegia / Q000209:etiology / Q000503:physiopathology; D016103:Spinal Fractures / Q000150:complications; D001750:Urinary Bladder, Neurogenic / Q000503:physiopathology
D009125:Muscle Relaxants, Central; D001418:Baclofen